Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 314, Issue 3, 2018, Pages L443-L460

  Frump, Andrea L ^a   Bonnet, Sébastien ^b   de Jesus Perez, Vinicio A ^c   Lahm, Tim ^a,d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LAVAL UNIVERSITY   (Canada)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APELIN; HYPOXIA INDUCIBLE FACTOR; MICRORNA; VASCULOTROPIN;

ADAPTIVE HEART RIGHT VENTRICLE REMODELING; ANGIOGENESIS; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; HUMAN; MALADAPTIVE HEART RIGHT VENTRICLE REMODELING; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; ANIMAL; COMPLICATION; HEART FAILURE; NEOVASCULARIZATION (PATHOLOGY);

ANIMALS; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; NEOVASCULARIZATION, PATHOLOGIC; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR REMODELING;

EID: 85043764212     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00374.2017     Document Type: Review

References (188)

1. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 121: 2747-2754, 2010. doi:10.1161/CIRCULATIONAHA.109.927681.
2. Adamis AP, Miller JW, Bernal M-T, D’Amico DJ, Folkman J, Yeo T-K, Yeo K-T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118: 445-450, 1994. doi:10.1016/S0002-9394(14)75794-0.
3. Akhavein F, St-Michel EJ, Seifert E, Rohlicek CV. Decreased left ventricular function, myocarditis, and coronary arteriolar medial thickening following monocrotaline administration in adult rats. J Appl Physiol (1985) 103: 287-295, 2007. doi:10.1152/japplphysiol.01509.2005.
4. Alastalo TP, Li M, Pde Jesus Perez V, Pham D, Sawada H, Wang JK, Koskenvuo M, Wang L, Freeman BA, Chang HY, Rabinovitch M. Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest 121: 3735-3746, 2011. doi:10.1172/JCI43382.
5. Alzoubi A, Toba M, Abe K, O’Neill KD, Rocic P, Fagan KA, McMurtry IF, Oka M. Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 304: H1708-H1718, 2013. doi:10.1152/ajpheart.00746.2012.
6. Andersen CU, Hilberg O, Mellemkjær S, Nielsen-Kudsk JE, Simonsen U. Apelin and pulmonary hypertension. Pulm Circ 1: 334-346, 2011. doi:10.4103/2045-8932.87299.
7. Archer SL. Riociguat for pulmonary hypertension—a glass half full. N Engl J Med 369: 386-388, 2013. doi:10.1056/NEJMe1306684.
8. Aspalter IM, Gordon E, Dubrac A, Ragab A, Narloch J, Vizán P, Geudens I, Collins RT, Franco CA, Abrahams CL, Thurston G, Fruttiger M, Rosewell I, Eichmann A, Gerhardt H. Alk1 and Alk5 inhibition by Nrp1 controls vascular sprouting downstream of Notch. Nat Commun 6: 7264, 2015. doi:10.1038/ncomms8264.
9. Beets K, Huylebroeck D, Moya IM, Umans L, Zwijsen A. Robustness in angiogenesis: notch and BMP shaping waves. Trends Genet 29: 140-149, 2013. doi:10.1016/j.tig.2012.11.008.
10. Blanco R, Gerhardt H. VEGF and Notch in tip and stalk cell selection. Cold Spring Harb Perspect Med 3: a006569, 2013. doi:10.1101/cshperspect.a006569.
11. Boerrigter BG, Bogaard HJ, Trip P, Groepenhoff H, Rietema H, Holverda S, Boonstra A, Postmus PE, Westerhof N, Vonk-Noordegraaf A. Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Chest 142: 1166-1174, 2012. doi:10.1378/chest.11-2798.
12. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of rightheart failure in pulmonary hypertension. Chest 135: 794-804, 2009. doi:10.1378/chest.08-0492.
13. Bogaard HJ, Mizuno S, Hussaini AA, Toldo S, Abbate A, Kraskauskas D, Kasper M, Natarajan R, Voelkel NF. Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. Am J Respir Crit Care Med 183: 1402-1410, 2011. doi:10.1164/rccm.201007-1106OC.
14. Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D, Smithson L, Ockaili R, McCord JM, Voelkel NF. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 120: 1951-1960, 2009. doi:10.1161/CIRCULATIONAHA.109.883843.
15. Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, Chau VQ, Hoke NN, Kraskauskas D, Kasper M, Salloum FN, Voelkel NF. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 182: 652-660, 2010. doi:10.1164/rccm.201003-0335OC.
16. Bohuslavová R, Kolárˇ F, Kuthanová L, Neckárˇ J, Tichopád A, Pavlinkova G. Gene expression profiling of sex differences in HIF1- dependent adaptive cardiac responses to chronic hypoxia. J Appl Physiol (1985) 109: 1195-1202, 2010. doi:10.1152/japplphysiol.00366.2010.
17. Bonnet S, Provencher S, Guignabert C, Perros F, Boucherat O, Schermuly RT, Hassoun PM, Rabinovitch M, Nicolls MR, Humbert M. Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 195: 583-595, 2017. doi:10.1164/rccm.201607-1515PP.
18. Boucherat O, Chabot S, Paulin R, Trinh I, Bourgeois A, Potus F, Lampron M-C, Lambert C, Breuils-Bonnet S, Nadeau V, Paradis R, Goncharova EA, Provencher S, Bonnet S. HDAC6: a novel histone deacetylase implicated in pulmonary arterial hypertension. Sci Rep 7: 4546, 2017. doi:10.1038/s41598-017-04874-4.
19. Boucherat O, Potus F, Bonnet S. microRNA and Pulmonary Hypertension. Adv Exp Med Biol 888: 237-252, 2015. doi:10.1007/978-3-319-22671-2_12.
20. Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, Silvola J, Saraste A, Jeltsch M, Korpisalo P, Carmeliet P, Lemström KB, Shibuya M, Ylä-Herttuala S, Alhonen L, Mervaala E, Andersson LC, Knuuti J, Alitalo K. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation 122: 1725-1733, 2010. doi:10.1161/CIRCULATIONAHA.110.957332.
21. Buysschaert I, Schmidt T, Roncal C, Carmeliet P, Lambrechts D. Genetics, epigenetics and pharmaco-(epi)genomics in angiogenesis. J Cell Mol Med 12, 6B: 2533-2551, 2008. doi:10.1111/j.1582-4934.2008.00515.x.
22. Cai Z, Zhong H, Bosch-Marce M, Fox-Talbot K, Wang L, Wei C, Trush MA, Semenza GL. Complete loss of ischaemic preconditioninginduced cardioprotection in mice with partial deficiency of HIF-1 alpha. Cardiovasc Res 77: 463-470, 2007. doi:10.1093/cvr/cvm035.
23. Carmeliet P. Angiogenesis in health and disease. Nat Med 9: 653-660, 2003. doi:10.1038/nm0603-653.
24. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307, 2011. doi:10.1038/nature10144.
25. Cavasin MA, Demos-Davies K, Horn TR, Walker LA, Lemon DD, Birdsey N, Weiser-Evans MC, Harral J, Irwin DC, Anwar A, Yeager ME, Li M, Watson PA, Nemenoff RA, Buttrick PM, Stenmark KR, McKinsey TA. Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ Res 110: 739-748, 2012. doi:10.1161/CIRCRESAHA.111.258426.
26. Chandra SM, Razavi H, Kim J, Agrawal R, Kundu RK, de Jesus Perez V, Zamanian RT, Quertermous T, Chun HJ. Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol 31: 814-820, 2011. doi:10.1161/ATVBAHA.110.219980.
27. Chaouat A, Weitzenblum E, Krieger J, Oswald M, Kessler R. Pulmonary hemodynamics in the obstructive sleep apnea syndrome. Results in 220 consecutive patients. Chest 109: 380-386, 1996. doi:10.1378/chest.109.2.380.
28. Chapman NA, Dupré DJ, Rainey JK. The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR. Biochem Cell Biol 92: 431-440, 2014. doi:10.1139/bcb-2014-0072.
29. Chaves-Almagro C, Castan-Laurell I, Dray C, Knauf C, Valet P, Masri B. Apelin receptors: From signaling to antidiabetic strategy. Eur J Pharmacol 763, Pt B: 149-159, 2015. doi:10.1016/j.ejphar.2015.05.017.
30. Chistiakov DA, Orekhov AN, Bobryshev YV. The role of miR-126 in embryonic angiogenesis, adult vascular homeostasis, and vascular repair and its alterations in atherosclerotic disease. J Mol Cell Cardiol 97: 47-55, 2016. doi:10.1016/j.yjmcc.2016.05.007.
31. Cho YJ, Han JY, Lee SG, Jeon BT, Choi WS, Hwang YS, Roh GS, Lee JD. Temporal changes of angiopoietins and Tie2 expression in rat lungs after monocrotaline-induced pulmonary hypertension. Comp Med 59: 350-356, 2009.
32. Ciuclan L, Bonneau O, Hussey M, Duggan N, Holmes AM, Good R, Stringer R, Jones P, Morrell NW, Jarai G, Walker C, Westwick J, Thomas M. A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 184: 1171-1182, 2011. doi:10.1164/rccm.201103-0412OC.
33. Collinson DJ, Donnelly R. Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation? Eur J Vasc Endovasc Surg 28: 9-23, 2004. doi:10.1016/j.ejvs.2004.03.021.
34. Compernolle V, Brusselmans K, Acker T, Hoet P, Tjwa M, Beck H, Plaisance S, Dor Y, Keshet E, Lupu F, Nemery B, Dewerchin M, Van Veldhoven P, Plate K, Moons L, Collen D, Carmeliet P. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 8: 702-710, 2002. doi:10.1038/nm721.
35. Cottin V, Le Pavec J, Prévot G, Mal H, Humbert M, Simonneau G, Cordier JF. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 35: 105-111, 2010. doi:10.1183/09031936.00038709.
36. Crawford TN, Alfaro DV III, Kerrison JB, Jablon EP. Diabetic retinopathy and angiogenesis. Curr Diabetes Rev 5: 8-13, 2009. doi:10.2174/157339909787314149.
37. Dai Z, Li M, Wharton J, Zhu MM, Zhao YY. Prolyl-4 Hydroxylase 2 (PHD2) Deficiency in Endothelial Cells and Hematopoietic Cells Induces Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension in Mice and Humans Through Hypoxia-Inducible Factor-2α. Circulation 133: 2447-2458, 2016. doi:10.1161/CIRCULATIONAHA.116.021494.
38. Dalzell JR, Rocchiccioli JP, Weir RA, Jackson CE, Padmanabhan N, Gardner RS, Petrie MC, McMurray JJ. The Emerging Potential of the Apelin-APJ System in Heart Failure. J Card Fail 21: 489-498, 2015. doi:10.1016/j.cardfail.2015.03.007.
39. de Jesus Perez VA. Molecular pathogenesis and current pathology of pulmonary hypertension. Heart Fail Rev 21: 239-257, 2016. doi:10.1007/s10741-015-9519-2.
40. De Raaf MA, Hussaini AA, Gomez-Arroyo J, Kraskaukas D, Farkas D, Happé C, Voelkel NF, Bogaard HJ. Histone deacetylase inhibition with trichostatin A does not reverse severe angioproliferative pulmonary hypertension in rats (2013 Grover Conference series). Pulm Circ 4: 237-243, 2014.
41. del Toro R, Prahst C, Mathivet T, Siegfried G, Kaminker JS, Larrivee B, Breant C, Duarte A, Takakura N, Fukamizu A, Penninger J, Eichmann A. Identification and functional analysis of endothelial tip cell-enriched genes. Blood 116: 4025-4033, 2010. doi:10.1182/blood-2010-02-270819.
42. Dias CA, Assad RS, Caneo LF, Abduch MC, Aiello VD, Dias AR, Marcial MB, Oliveira SA. Reversible pulmonary trunk banding. II. An experimental model for rapid pulmonary ventricular hypertrophy. J Thorac Cardiovasc Surg 124: 999-1006, 2002. doi:10.1067/mtc.2002.124234.
43. Drake JI, Bogaard HJ, Mizuno S, Clifton B, Xie B, Gao Y, Dumur CI, Fawcett P, Voelkel NF, Natarajan R. Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. Am J Respir Cell Mol Biol 45: 1239-1247, 2011. doi:10.1165/rcmb.2010-0412OC.
44. Eddahibi S, Humbert M, Sediame S, Chouaid C, Partovian C, Maître B, Teiger E, Rideau D, Simonneau G, Sitbon O, Adnot S. Imbalance between platelet vascular endothelial growth factor and platelet- derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. Am J Respir Crit Care Med 162: 1493-1499, 2000. doi:10.1164/ajrccm.162.4.2003124.
45. Erzurum S, Rounds SI, Stevens T, Aldred M, Aliotta J, Archer SL, Asosingh K, Balaban R, Bauer N, Bhattacharya J, Bogaard H, Choudhary G, Dorn GW II, Dweik R, Fagan K, Fallon M, Finkel T, Geraci M, Gladwin MT, Hassoun PM, Humbert M, Kaminski N, Kawut SM, Loscalzo J, McDonald D, McMurtry IF, Newman J, Nicolls M, Rabinovitch M, Shizuru J, Oka M, Polgar P, Rodman D, Schumacker P, Stenmark K, Tuder R, Voelkel N, Sullivan E, Weinshilboum R, Yoder MC, Zhao Y, Gail D, Moore TM. Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report. Am J Respir Crit Care Med 182: 1554-1562, 2010. doi:10.1164/rccm.201006-0869WS.
46. Falcão-Pires I, Gonçalves N, Henriques-Coelho T, Moreira-Gonçalves D, Roncon-Albuquerque R Jr, Leite-Moreira AF. Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 296: H2007-H2014, 2009. doi:10.1152/ajpheart.00089.2009.
47. Fan XF, Wang Q, Mao SZ, Hu LG, Hong L, Tian LX, Gao YQ, Gong YS. [Protective and therapeutic effect of apelin on chronic hypoxic pulmonary hypertension in rats]. Zhongguo Ying Yong Sheng Li Xue Za Zhi 26: 9-12, 2010.
48. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003. doi:10.1038/nm0603-669.
49. Fong GH, Zhang L, Bryce DM, Peng J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development 126: 3015-3025, 1999.
50. Fraisl P, Mazzone M, Schmidt T, Carmeliet P. Regulation of angiogenesis by oxygen and metabolism. Dev Cell 16: 167-179, 2009. doi:10.1016/j.devcel.2009.01.003.
51. Friedberg MK, Redington AN. Right versus left ventricular failure: differences, similarities, and interactions. Circulation 129: 1033-1044, 2014. doi:10.1161/CIRCULATIONAHA.113.001375.
52. Frump AL, Goss KN, Vayl A, Albrecht M, Fisher A, Tursunova R, Fierst J, Whitson J, Cucci AR, Brown MB, Lahm T. Estradiol improves right ventricular function in rats with severe angioproliferative pulmonary hypertension: effects of endogenous and exogenous sex hormones. Am J Physiol Lung Cell Mol Physiol 308: L873-L890, 2015. doi:10.1152/ajplung.00006.2015.
53. Geudens I, Gerhardt H. Coordinating cell behaviour during blood vessel formation. Development 138: 4569-4583, 2011. doi:10.1242/dev.062323.
54. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 37: 183-188, 2001. doi:10.1016/S0735-1097(00)01102-5.
55. Goetze JP, Rehfeld JF, Carlsen J, Videbaek R, Andersen CB, Boesgaard S, Friis-Hansen L. Apelin: a new plasma marker of cardiopulmonary disease. Regul Pept 133: 134-138, 2006. doi:10.1016/j.regpep.2005.09.032.
56. Gomez-Arroyo J, Mizuno S, Szczepanek K, Van Tassell B, Natarajan R, dos Remedios CG, Drake JI, Farkas L, Kraskauskas D, Wijesinghe DS, Chalfant CE, Bigbee J, Abbate A, Lesnefsky EJ, Bogaard HJ, Voelkel NF. Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension. Circ Heart Fail 6: 136-144, 2013. doi:10.1161/CIRCHEARTFAILURE.111.966127.
57. Gomez-Arroyo J, Saleem SJ, Mizuno S, Syed AA, Bogaard HJ, Abbate A, Taraseviciene-Stewart L, Sung Y, Kraskauskas D, Farkas D, Conrad DH, Nicolls MR, Voelkel NF. A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects. Am J Physiol Lung Cell Mol Physiol 302: L977-L991, 2012. doi:10.1152/ajplung.00362.2011.
58. Gomez-Arroyo JG, Farkas L, Alhussaini AA, Farkas D, Kraskauskas D, Voelkel NF, Bogaard HJ. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol 302: L363-L369, 2012. doi:10.1152/ajplung.00212.2011.
59. Gómez A, Bialostozky D, Zajarias A, Santos E, Palomar A, Martínez ML, Sandoval J. Right ventricular ischemia in patients with primary pulmonary hypertension. J Am Coll Cardiol 38: 1137-1142, 2001. doi:10.1016/S0735-1097(01)01496-6.
60. Gomez A, Mink S. Interaction between effects of hypoxia and hypercapnia on altering left ventricular relaxation and chamber stiffness in dogs. Am Rev Respir Dis 146: 313-320, 1992. doi:10.1164/ajrccm/146.2.313.
61. Graham BB, Koyanagi D, Kandasamy B, Tuder RM. Right ventricle vasculature in human pulmonary hypertension assessed by stereology. Am J Respir Crit Care Med 196: 1075-1077, 2017. doi:10.1164/rccm.201702-0425LE.
62. Hagberg C, Mehlem A, Falkevall A, Muhl L, Eriksson U. Endothelial fatty acid transport: role of vascular endothelial growth factor B. Physiology (Bethesda) 28: 125-134, 2013.
63. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100: 57-70, 2000. doi:10.1016/S0092-8674(00)81683-9.
64. Handoko ML, de Man FS, Happé CM, Schalij I, Musters RJ, Westerhof N, Postmus PE, Paulus WJ, van der Laarse WJ, Vonk- Noordegraaf A. Opposite effects of training in rats with stable and progressive pulmonary hypertension. Circulation 120: 42-49, 2009. doi:10.1161/CIRCULATIONAHA.108.829713.
65. Hessel MH, Steendijk P, den Adel B, Schutte CI, van der Laarse A. Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am J Physiol Heart Circ Physiol 291: H2424-H2430, 2006. doi:10.1152/ajpheart.00369.2006.
66. Hirose S, Hosoda Y, Furuya S, Otsuki T, Ikeda E. Expression of vascular endothelial growth factor and its receptors correlates closely with formation of the plexiform lesion in human pulmonary hypertension. Pathol Int 50: 472-479, 2000. doi:10.1046/j.1440-1827.2000.01068.x.
67. Hoelscher SC, Doppler SA, Dreßen M, Lahm H, Lange R, Krane M. MicroRNAs: pleiotropic players in congenital heart disease and regeneration. J Thorac Dis 9, Suppl 1: S64-S81, 2017. doi:10.21037/jtd.2017.03.149.
68. Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa- Hahnle K, Jing ZC, Gibbs JS. A global view of pulmonary hypertension. Lancet Respir Med 4: 306-322, 2016. doi:10.1016/S2213-2600(15)00543-3.
69. Huang Y, Hickey RP, Yeh JL, Liu D, Dadak A, Young LH, Johnson RS, Giordano FJ. Cardiac myocyte-specific HIF-1alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart. FASEB J 18: 1138-1140, 2004.
70. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaïci A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Cottin V, Degano B, Jaïs X, Montani D, Souza R, Simonneau G. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122: 156-163, 2010. doi:10.1161/CIRCULATIONAHA.109.911818.
71. Hyduk A, Croft JB, Ayala C, Zheng K, Zheng ZJ, Mensah GA. Pulmonary hypertension surveillance-United States, 1980-2002. MMWR Surveill Summ 54: 1-28, 2005.
72. Iwanaga Y, Kihara Y, Takenaka H, Kita T. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: Possible role of angiotensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol 41: 798-806, 2006. doi:10.1016/j.yjmcc.2006.07.004.
73. Japp AG, Newby DE. The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol 75: 1882-1892, 2008. doi:10.1016/j.bcp.2007.12.015.
74. Jin Y, Kaluza D, Jakobsson L. VEGF, Notch and TGFβ/BMPs in regulation of sprouting angiogenesis and vascular patterning. Biochem Soc Trans 42: 1576-1583, 2014. doi:10.1042/BST20140231.
75. Kaneko N, Matsuda R, Toda M, Shimamoto K. Three-dimensional reconstruction of the human capillary network and the intramyocardial micronecrosis. Am J Physiol Heart Circ Physiol 300: H754-H761, 2011. doi:10.1152/ajpheart.00486.2010.
76. Kapitsinou PP, Rajendran G, Astleford L, Michael M, Schonfeld MP, Fields T, Shay S, French JL, West J, Haase VH. The endothelial prolyl-4-hydroxylase domain 2/hypoxia-inducible factor 2 axis regulates pulmonary artery pressure in mice. Mol Cell Biol 36: 1584-1594, 2016. doi:10.1128/MCB.01055-15.
77. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90: 10705-10709, 1993. doi:10.1073/pnas.90.22.10705.
78. Kido M, Du L, Sullivan CC, Li X, Deutsch R, Jamieson SW, Thistlethwaite PA. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol 46: 2116-2124, 2005. doi:10.1016/j.jacc.2005.08.045.
79. Kidoya H, Takakura N. Biology of the apelin-APJ axis in vascular formation. J Biochem 152: 125-131, 2012. doi:10.1093/jb/mvs071.
80. Kim J. Apelin-APJ signaling: a potential therapeutic target for pulmonary arterial hypertension. Mol Cells 37: 196-201, 2014. doi:10.14348/molcells.2014.2308.
81. Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept 118: 119-125, 2004. doi:10.1016/j.regpep.2003.11.002.
82. Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept 126: 233-240, 2005. doi:10.1016/j.regpep.2004.10.019.
83. Kobayashi H, Yoshimura Y, Suzuki H, Hosoda Y. Regional difference of capillary-to-fiber ratio in the heart of monocrotaline-treated rats. Basic Res Cardiol 89: 118-127, 1994.
84. Kolb TM, Peabody J, Baddoura P, Fallica J, Mock JR, Singer BD, D’Alessio FR, Damarla M, Damico RL, Hassoun PM. Right ventricular angiogenesis is an early adaptive response to chronic hypoxiainduced pulmonary hypertension. Microcirculation 22: 724-736, 2015. doi:10.1111/micc.12247.
85. Kotch LE, Iyer NV, Laughner E, Semenza GL. Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev Biol 209: 254-267, 1999. doi:10.1006/dbio.1999.9253.
86. Kuba K, Zhang L, Imai Y, Arab S, Chen M, Maekawa Y, Leschnik M, Leibbrandt A, Markovic M, Schwaighofer J, Beetz N, Musialek R, Neely GG, Komnenovic V, Kolm U, Metzler B, Ricci R, Hara H, Meixner A, Nghiem M, Chen X, Dawood F, Wong KM, Sarao R, Cukerman E, Kimura A, Hein L, Thalhammer J, Liu PP, Penninger JM. Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. Circ Res 101: e32-e42, 2008. doi:10.1161/CIRCRESAHA.107.158659.
87. Labrousse-Arias D, Castillo-González R, Rogers NM, Torres-Capelli M, Barreira B, Aragonés J, Cogolludo Á, Isenberg JS, Calzada MJ. HIF-2α-mediated induction of pulmonary thrombospondin-1 contributes to hypoxia-driven vascular remodelling and vasoconstriction. Cardiovasc Res 109: 115-130, 2016. doi:10.1093/cvr/cvv243.
88. Lahm T, Albrecht M, Fisher AJ, Selej M, Patel NG, Brown JA, Justice MJ, Brown MB, Van Demark M, Trulock KM, Dieudonne D, Reddy JG, Presson RG, Petrache I. 17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects. Am J Respir Crit Care Med 185: 965-980, 2012. doi:10.1164/rccm.201107-1293OC.
89. Lahm T, Tuder RM, Petrache I. Progress in solving the sex hormone paradox in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 307: L7-L26, 2014. doi:10.1152/ajplung.00337.2013.
90. Lajoie AC, Lauzière G, Lega J-C, Lacasse Y, Martin S, Simard S, Bonnet S, Provencher S. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med 4: 291-305, 2016. doi:10.1016/S2213-2600(16)00027-8.
91. Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, Osmond DH, George SR, O’Dowd BF. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 74: 34-41, 2000. doi:10.1046/j.1471-4159.2000.0740034.x.
92. Lima J Jr, Batty JA, Sinclair H, Kunadian V. MicroRNAs in ischemic heart disease: from pathophysiology to potential clinical applications. Cardiol Rev 25: 117-125, 2017. doi:10.1097/CRD.0000000000000114.
93. Lin Q, Lu J, Yanagisawa H, Webb R, Lyons GE, Richardson JA, Olson EN. Requirement of the MADS-box transcription factor MEF2C for vascular development. Development 125: 4565-4574, 1998.
94. Liu Q, Hu T, He L, Huang X, Tian X, Zhang H, He L, Pu W, Zhang L, Sun H, Fang J, Yu Y, Duan S, Hu C, Hui L, Zhang H, Quertermous T, Xu Q, Red-Horse K, Wythe JD, Zhou B. Genetic targeting of sprouting angiogenesis using Apln-CreER. Nat Commun 6: 6020, 2015. doi:10.1038/ncomms7020.
95. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel- Smoller S, Wong ND, Wylie-Rosett J; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation 121: 948-954, 2010. doi:10.1161/CIRCULATIONAHA.109.192666.
96. Maiti D, Xu Z, Duh EJ. Vascular endothelial growth factor induces MEF2C and MEF2-dependent activity in endothelial cells. Invest Ophthalmol Vis Sci 49: 3640-3648, 2008. doi:10.1167/iovs.08-1760.
97. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 40: 294-309, 2010. doi:10.1016/j.molcel.2010.09.022.
98. Maron BA, Choudhary G, Khan UA, Jankowich MD, McChesney H, Ferrazzani SJ, Gaddam S, Sharma S, Opotowsky AR, Bhatt DL, Rocco TP, Aragam JR. Clinical profile and underdiagnosis of pulmonary hypertension in US veteran patients. Circ Heart Fail 6: 906-912, 2013. doi:10.1161/CIRCHEARTFAILURE.112.000091.
99. Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, Joynt KE, Kass DJ, Stephens T, Stanislawski MA, Swenson ER, Goldstein RH, Leopold JA, Zamanian RT, Elwing JM, Plomondon ME, Grunwald GK, Barón AE, Rumsfeld JS, Choudhary G. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circulation 133: 1240-1248, 2016. doi:10.1161/CIRCULATIONAHA.115.020207.
100. Matori H, Umar S, Nadadur RD, Sharma S, Partow-Navid R, Afkhami M, Amjedi M, Eghbali M. Genistein, a soy phytoestrogen, reverses severe pulmonary hypertension and prevents right heart failure in rats. Hypertension 60: 425-430, 2012. doi:10.1161/HYPERTENSIONAHA.112.191445.
101. Meloche J, Lampron MC, Nadeau V, Maltais M, Potus F, Lambert C, Tremblay E, Vitry G, Breuils-Bonnet S, Boucherat O, Charbonneau E, Provencher S, Paulin R, Bonnet S. Implication of inflammation and epigenetic readers in coronary artery remodeling in patients with pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 37: 1513-1523, 2017. doi:10.1161/ATVBAHA.117.309156.
102. Mohammed SF, Hussain I, AbouEzzeddine OF, Takahama H, Kwon SH, Forfia P, Roger VL, Redfield MM. Right ventricular function in heart failure with preserved ejection fraction: a community-based study. Circulation 130: 2310-2320, 2014. doi:10.1161/CIRCULATIONAHA.113.008461.
103. Morrison DA, Adcock K, Collins CM, Goldman S, Caldwell JH, Schwarz MI. Right ventricular dysfunction and the exercise limitation of chronic obstructive pulmonary disease. J Am Coll Cardiol 9: 1219-1229, 1987. doi:10.1016/S0735-1097(87)80459-X.
104. Moschetta M, Mishima Y, Sahin I, Manier S, Glavey S, Vacca A, Roccaro AM, Ghobrial IM. Role of endothelial progenitor cells in cancer progression. Biochim Biophys Acta 1846: 26-39, 2014.
105. Mühlfeld C. Quantitative morphology of the vascularisation of organs: A stereological approach illustrated using the cardiac circulation. Ann Anat 196: 12-19, 2014. doi:10.1016/j.aanat.2012.10.010.
106. Nagendran J, Sutendra G, Paterson I, Champion HC, Webster L, Chiu B, Haromy A, Rebeyka IM, Ross DB, Michelakis ED. Endothelin axis is upregulated in human and rat right ventricular hypertrophy. Circ Res 112: 347-354, 2013. doi:10.1161/CIRCRESAHA.111.300448.
107. Naito AT, Okada S, Minamino T, Iwanaga K, Liu ML, Sumida T, Nomura S, Sahara N, Mizoroki T, Takashima A, Akazawa H, Nagai T, Shiojima I, Komuro I. Promotion of CHIP-mediated p53 degradation protects the heart from ischemic injury. Circ Res 106: 1692-1702, 2010. doi:10.1161/CIRCRESAHA.109.214346.
108. Narmoneva DA, Vukmirovic R, Davis ME, Kamm RD, Lee RT. Endothelial cells promote cardiac myocyte survival and spatial reorganization: implications for cardiac regeneration. Circulation 110: 962-968, 2004. doi:10.1161/01.CIR.0000140667.37070.07.
109. Nicoli S, Standley C, Walker P, Hurlstone A, Fogarty KE, Lawson ND. MicroRNA-mediated integration of haemodynamics and Vegf signalling during angiogenesis. Nature 464: 1196-1200, 2010. doi:10.1038/nature08889.
110. Nicolls MR, Mizuno S, Taraseviciene-Stewart L, Farkas L, Drake JI, Al Husseini A, Gomez-Arroyo JG, Voelkel NF, Bogaard HJ. New models of pulmonary hypertension based on VEGF receptor blockadeinduced endothelial cell apoptosis. Pulm Circ 2: 434-442, 2012. doi:10.4103/2045-8932.105031.
111. Ohtani K, Dimmeler S. Control of cardiovascular differentiation by microRNAs. Basic Res Cardiol 106: 5-11, 2011. doi:10.1007/s00395-010-0139-7.
112. Oka T, Akazawa H, Naito AT, Komuro I. Angiogenesis and cardiac hypertrophy: maintenance of cardiac function and causative roles in heart failure. Circ Res 114: 565-571, 2014. doi:10.1161/CIRCRESAHA.114.300507.
113. Okada K, Tanaka Y, Bernstein M, Zhang W, Patterson GA, Botney MD. Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. Am J Pathol 151: 1019-1025, 1997.
114. Ostádal B, Urbanová D, Ressl J, Procházka J, Pelouch V, Widimský J. Changes of the right and left ventricles in rats exposed to intermittent high altitude hypoxia. Cor Vasa 23: 111-120, 1981.
115. Pan LC, Wilson DW, Segall HJ. Strain differences in the response of Fischer 344 and Sprague-Dawley rats to monocrotaline induced pulmonary vascular disease. Toxicology 79: 21-35, 1993. doi:10.1016/0300-483X(93)90203-5.
116. Papaioannou AI, Zakynthinos E, Kostikas K, Kiropoulos T, Koutsokera A, Ziogas A, Koutroumpas A, Sakkas L, Gourgoulianis KI, Daniil ZD. Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis. BMC Pulm Med 9: 18, 2009. doi:10.1186/1471-2466-9-18.
117. Partovian C, Adnot S, Eddahibi S, Teiger E, Levame M, Dreyfus P, Raffestin B, Frelin C. Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension. Am J Physiol 275: H1948-H1956, 1998.
118. Patan S. Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling. J Neurooncol 50: 1-15, 2000. doi:10.1023/A:1006493130855.
119. Paulin R, Sutendra G, Gurtu V, Dromparis P, Haromy A, Provencher S, Bonnet S, Michelakis ED. A miR-208-Mef2 axis drives the decompensation of right ventricular function in pulmonary hypertension. Circ Res 116: 56-69, 2015. doi:10.1161/CIRCRESAHA.115.303910.
120. Peng J, Zhang L, Drysdale L, Fong GH. The transcription factor EPAS-1/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling. Proc Natl Acad Sci USA 97: 8386-8391, 2000. doi:10.1073/pnas.140087397.
121. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P; Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350: 2257-2264, 2004. doi:10.1056/NEJMoa032274.
122. Piao L, Fang YH, Parikh K, Ryan JJ, Toth PT, Archer SL. Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. J Mol Med (Berl) 91: 1185-1197, 2013. doi:10.1007/s00109-013-1064-7.
123. Potus F, Malenfant S, Graydon C, Mainguy V, Tremblay È, Breuils- Bonnet S, Ribeiro F, Porlier A, Maltais F, Bonnet S, Provencher S. Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension. Am J Respir Crit Care Med 190: 318-328, 2014.
124. Potus F, Ruffenach G, Dahou A, Thebault C, Breuils-Bonnet S, Tremblay È, Nadeau V, Paradis R, Graydon C, Wong R, Johnson I, Paulin R, Lajoie AC, Perron J, Charbonneau E, Joubert P, Pibarot P, Michelakis ED, Provencher S, Bonnet S. Downregulation of MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension. Circulation 132: 932-943, 2015. doi:10.1161/CIRCULATIONAHA.115.016382.
125. Rain S, Handoko ML, Trip P, Gan CT, Westerhof N, Stienen GJ, Paulus WJ, Ottenheijm CA, Marcus JT, Dorfmüller P, Guignabert C, Humbert M, Macdonald P, Dos Remedios C, Postmus PE, Saripalli C, Hidalgo CG, Granzier HL, Vonk-Noordegraaf A, van der Velden J, de Man FS. Right ventricular diastolic impairment in patients with pulmonary arterial hypertension. Circulation 128: 2016-2025, 2013. doi:10.1161/CIRCULATIONAHA.113.001873.
126. Reddy S, Bernstein D. Molecular Mechanisms of Right Ventricular Failure. Circulation 132: 1734-1742, 2015. doi:10.1161/CIRCULATIONAHA.114.012975.
127. Reddy S, Zhao M, Hu DQ, Fajardo G, Hu S, Ghosh Z, Rajagopalan V, Wu JC, Bernstein D. Dynamic microRNA expression during the transition from right ventricular hypertrophy to failure. Physiol Genomics 44: 562-575, 2012. doi:10.1152/physiolgenomics.00163.2011.
128. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289: 194-202, 2003. doi:10.1001/jama.289.2.194.
129. Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 11: 73-91, 1995. doi:10.1146/annurev.cb.11.110195.000445.
130. Rivera-Lebron BN, Forfia PR, Kreider M, Lee JC, Holmes JH, Kawut SM. Echocardiographic and hemodynamic predictors of mortality in idiopathic pulmonary fibrosis. Chest 144: 564-570, 2013. doi:10.1378/chest.12-2298.
131. Ruiter G, Ying Wong Y, de Man FS, Louis Handoko M, Jaspers RT, Postmus PE, Westerhof N, Niessen HW, van der Laarse WJ, Vonk- Noordegraaf A. Right ventricular oxygen supply parameters are decreased in human and experimental pulmonary hypertension. J Heart Lung Transplant 32: 231-240, 2013. doi:10.1016/j.healun.2012.09.025.
132. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17: 3005-3015, 1998. doi:10.1093/emboj/17.11.3005.
133. Ryan JJ, Archer SL. The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res 115: 176-188, 2014. doi:10.1161/CIRCRESAHA.113.301129.
134. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, Akazawa H, Tateno K, Kayama Y, Harada M, Shimizu I, Asahara T, Hamada H, Tomita S, Molkentin JD, Zou Y, Komuro I. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446: 444-448, 2007. doi:10.1038/nature05602.
135. Santoro MM, Nicoli S. miRNAs in endothelial cell signaling: the endomiRNAs. Exp Cell Res 319: 1324-1330, 2013. doi:10.1016/j.yexcr.2012.12.009.
136. Schäfer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, Milting H, Kast R, Klein M. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. Cardiovasc Res 82: 30-39, 2009. doi:10.1093/cvr/cvp002.
137. Seeger W, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galiè N, Ghio S, Gibbs S, Martinez FJ, Semigran MJ, Simonneau G, Wells AU, Vachiéry JL. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 62, Suppl: D109-D116, 2013. doi:10.1016/j.jacc.2013.10.036.
138. Selimovic N, Bergh CH, Andersson B, Sakiniene E, Carlsten H, Rundqvist B. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J 34: 662-668, 2009. doi:10.1183/09031936.00174908.
139. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 148: 399-408, 2012. doi:10.1016/j.cell.2012.01.021.
140. Semenza GL. Pulmonary vascular responses to chronic hypoxia mediated by hypoxia-inducible factor 1. Proc Am Thorac Soc 2: 68-70, 2005.
141. doi:10.1513/pats.200404-029MS.
142. Senger DR, Davis GE. Angiogenesis. Cold Spring Harb Perspect Biol 3: a005090, 2011. doi:10.1101/cshperspect.a005090.
143. Serpi R, Tolonen AM, Huusko J, Rysä J, Tenhunen O, Ylä-Herttuala S, Ruskoaho H. Vascular endothelial growth factor-B gene transfer prevents angiotensin II-induced diastolic dysfunction via proliferation and capillary dilatation in rats. Cardiovasc Res 89: 204-213, 2011. doi:10.1093/cvr/cvq267.
144. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62-66, 1995. doi:10.1038/376062a0.
145. Sharma S, Taegtmeyer H, Adrogue J, Razeghi P, Sen S, Ngumbela K, Essop MF. Dynamic changes of gene expression in hypoxia-induced right ventricular hypertrophy. Am J Physiol Heart Circ Physiol 286: H1185-H1192, 2004. doi:10.1152/ajpheart.00916.2003.
146. Sheikh AY, Chun HJ, Glassford AJ, Kundu RK, Kutschka I, Ardigo D, Hendry SL, Wagner RA, Chen MM, Ali ZA, Yue P, Huynh DT, Connolly AJ, Pelletier MP, Tsao PS, Robbins RC, Quertermous T. In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure. Am J Physiol Heart Circ Physiol 294: H88-H98, 2008. doi:10.1152/ajpheart.00935.2007.
147. Shimoda LA, Semenza GL. HIF and the lung: role of hypoxia-inducible factors in pulmonary development and disease. Am J Respir Crit Care Med 183: 152-156, 2011. doi:10.1164/rccm.201009-1393PP.
148. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS, Walsh K. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115: 2108-2118, 2005. doi:10.1172/JCI24682.
149. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62, Suppl: D34-D41, 2013. doi:10.1016/j.jacc.2013.10.029.
150. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 297: L1013-L1032, 2009. doi:10.1152/ajplung.00217.2009.
151. Strasser GA, Kaminker JS, Tessier-Lavigne M. Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching. Blood 115: 5102-5110, 2010. doi:10.1182/blood-2009-07-230284.
152. Sutendra G, Dromparis P, Paulin R, Zervopoulos S, Haromy A, Nagendran J, Michelakis ED. A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. J Mol Med (Berl) 91: 1315-1327, 2013. doi:10.1007/s00109-013-1059-4.
153. Sutendra G, Michelakis ED. Pulmonary arterial hypertension: challenges in translational research and a vision for change. Sci Transl Med 5: 208sr5, 2013. doi:10.1126/scitranslmed.3005428.
154. Szokodi I, Tavi P, Földes G, Voutilainen-Myllylä S, Ilves M, Tokola H, Pikkarainen S, Piuhola J, Rysä J, Tóth M, Ruskoaho H. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 91: 434-440, 2002. doi:10.1161/01.RES.0000033522.37861.69.
155. Tabuchi T, Satoh M, Itoh T, Nakamura M. MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression. Clin Sci (Lond) 123: 161-171, 2012. doi:10.1042/CS20110563.
156. Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18: 2221-2230, 1999. doi:10.1038/sj.onc.1202527.
157. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15: 427-438, 2001. doi:10.1096/fj.00-0343com.
158. Tempel D, de Boer M, van Deel ED, Haasdijk RA, Duncker DJ, Cheng C, Schulte-Merker S, Duckers HJ. Apelin enhances cardiac neovascularization after myocardial infarction by recruiting aplnr+ circulating cells. Circ Res 111: 585-598, 2012. doi:10.1161/CIRCRESAHA.111.262097.
159. Thum T, Batkai S. MicroRNAs in right ventricular (dys)function (2013 Grover Conference series). Pulm Circ 4: 185-190, 2014. doi:10.1086/675981.
160. Tian H, Hammer RE, Matsumoto AM, Russell DW, McKnight SL. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 12: 3320-3324, 1998. doi:10.1101/gad.12.21.3320.
161. Tuder RM, Archer SL, Dorfmüller P, Erzurum SC, Guignabert C, Michelakis E, Rabinovitch M, Schermuly R, Stenmark KR, Morrell NW. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 62, Suppl: D4-D12, 2013. doi:10.1016/j.jacc.2013.10.025.
162. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 95: 1798-1807, 1995. doi:10.1172/JCI117858.
163. Tuder RM, Yun JH, Bhunia A, Fijalkowska I. Hypoxia and chronic lung disease. J Mol Med (Berl) 85: 1317-1324, 2007. doi:10.1007/s00109-007-0280-4.
164. Turek Z, Grandtner M, Kreuzer F. Cardiac hypertrophy, capillary and muscle fiber density, muscle fiber diameter, capillary radius and diffusion distance in the myocardium of growing rats adapted to a simulated altitude of 3500 m. Pflugers Arch 335: 19-28, 1972. doi:10.1007/BF00586932.
165. Turek Z, Hoofd LJ, Ringnalda BE, Rakusan K. Myocardial capillarity of rats exposed to simulated high altitude. Adv Exp Med Biol 191: 249-255, 1985. doi:10.1007/978-1-4684-3291-6-25.
166. Tvorogov D, Anisimov A, Zheng W, Leppänen VM, Tammela T, Laurinavicius S, Holnthoner W, Heloterä H, Holopainen T, Jeltsch M, Kalkkinen N, Lankinen H, Ojala PM, Alitalo K. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell 18: 630-640, 2010. doi:10.1016/j.ccr.2010.11.001.
167. Vachiéry JL, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galiè N, Ghio S, Gibbs JS, Martinez F, Semigran M, Simonneau G, Wells A, Seeger W. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 62, Suppl: D100-D108, 2013. doi:10.1016/j.jacc.2013.10.033.
168. Vaillancourt M, Ruffenach G, Meloche J, Bonnet S. Adaptation and remodelling of the pulmonary circulation in pulmonary hypertension. Can J Cardiol 31: 407-415, 2015. doi:10.1016/j.cjca.2014.10.023.
169. van Albada ME, Berger RM, Niggebrugge M, van Veghel R, Cromme-Dijkhuis AH, Schoemaker RG. Prostacyclin therapy increases right ventricular capillarisation in a model for flow-associated pulmonary hypertension. Eur J Pharmacol 549: 107-116, 2006. doi:10. 1016/j.ejphar.2006.08.016.
170. van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ, Boonstra A, Marques KM, Westerhof N, Vonk- Noordegraaf A. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 58: 2511-2519, 2011. doi:10.1016/j.jacc.2011.06.068.
171. van Wolferen SA, Marcus JT, Westerhof N, Spreeuwenberg MD, Marques KM, Bronzwaer JG, Henkens IR, Gan CT, Boonstra A, Postmus PE, Vonk-Noordegraaf A. Right coronary artery flow impairment in patients with pulmonary hypertension. Eur Heart J 29: 120-127, 2007. doi:10.1093/eurheartj/ehm567.
172. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89: e1-e7, 2001. doi:10.1161/hh1301.093953.
173. Veith C, Schermuly RT, Brandes RP, Weissmann N. Molecular mechanisms of hypoxia-inducible factor-induced pulmonary arterial smooth muscle cell alterations in pulmonary hypertension. J Physiol 594: 1167-1177, 2016. doi:10.1113/JP270689.
174. Voelkel NF, Gomez-Arroyo J. The role of vascular endothelial growth factor in pulmonary arterial hypertension. The angiogenesis paradox. Am J Respir Cell Mol Biol 51: 474-484, 2014. doi:10.1165/rcmb.2014-0045TR.
175. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB; National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 114: 1883-1891, 2006. doi:10.1161/CIRCULATIONAHA.106.632208.
176. Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, Naeije R, Newman J, Oudiz RJ, Provencher S, Torbicki A, Voelkel NF, Hassoun PM. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol 62, Suppl: D22-D33, 2013. doi:10.1016/j.jacc.2013.10.027.
177. Vonk Noordegraaf A, Westerhof BE, Westerhof N. The relationship between the right ventricle and its load in pulmonary hypertension. J Am Coll Cardiol 69: 236-243, 2017. doi:10.1016/j.jacc.2016.10.047.
178. Wang H, Cai J. The role of microRNAs in heart failure. Biochim Biophys Acta 1863: 2019-2030, 2017. doi:10.1016/j.bbadis.2016.11.034.
179. Ware JA, Simons M. Angiogenesis in ischemic heart disease. Nat Med 3: 158-164, 1997. doi:10.1038/nm0297-158.
180. Werchan PM, Summer WR, Gerdes AM, McDonough KH. Right ventricular performance after monocrotaline-induced pulmonary hypertension. Am J Physiol 256: H1328-H1336, 1989.
181. Yang P, Maguire JJ, Davenport AP. Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system. Trends Pharmacol Sci 36: 560-567, 2015. doi:10.1016/j.tips.2015.06.002.
182. Yang P, Read C, Kuc RE, Buonincontri G, Southwood M, Torella R, Upton PD, Crosby A, Sawiak SJ, Carpenter TA, Glen RC, Morrell NW, Maguire JJ, Davenport AP. Elabela/Toddler is an endogenous agonist of the apelin APJ receptor in the adult cardiovascular system, and exogenous administration of the peptide compensates for the downregulation of its expression in pulmonary arterial hypertension. Circulation 135: 1160-1173, 2017. doi:10.1161/CIRCULATIONAHA.116.023218.
183. Yang X, Zhu W, Zhang P, Chen K, Zhao L, Li J, Wei M, Liu M. Apelin-13 stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in myocardial microvascular endothelial cells. Mol Med Rep 9: 1590-1596, 2014. doi:10.3892/mmr.2014.1984.
184. Yoshida M, Shiojima I, Ikeda H, Komuro I. Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. J Mol Cell Cardiol 47: 698-705, 2009. doi:10.1016/j.yjmcc.2009.07.024.
185. Yuan K, Orcholski ME, Panaroni C, Shuffle EM, Huang NF, Jiang X, Tian W, Vladar EK, Wang L, Nicolls MR, Wu JY, de Jesus Perez VA. Activation of the Wnt/planar cell polarity pathway is required for pericyte recruitment during pulmonary angiogenesis. Am J Pathol 185: 69-84, 2015. doi:10.1016/j.ajpath.2014.09.013.
186. Zhao L, Chen CN, Hajji N, Oliver E, Cotroneo E, Wharton J, Wang D, Li M, McKinsey TA, Stenmark KR, Wilkins MR. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 126: 455-467, 2012. doi:10.1161/CIRCULATIONAHA.112.103176.
187. Zhong JC, Yu XY, Huang Y, Yung LM, Lau CW, Lin SG. Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovasc Res 74: 388-395, 2007. doi:10.1016/j.cardiores.2007.02.002.
188. Zhuang G, Yu K, Jiang Z, Chung A, Yao J, Ha C, Toy K, Soriano R, Haley B, Blackwood E, Sampath D, Bais C, Lill JR, Ferrara N. Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases. Sci Signal 6: ra25, 2013. doi:10.1126/scisignal.2003572.